Trifluridine/tipiracil plus bevacizumab as a first‐line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial

BACKGROUND: A previous Phase I/II study demonstrated that TAS‐102 (trifluridine/tipiracil [FTD/TPI]) plus bevacizumab (Bev) has encouraging efficacy and controllable safety for patients with previously treated metastatic colorectal cancer. Therefore, we designed for assessing the efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Oki, Eiji, Makiyama, Akitaka, Miyamoto, Yuji, Kotaka, Masahiko, Kawanaka, Hirofumi, Miwa, Keisuke, Kabashima, Akira, Noguchi, Tomohiro, Yuge, Kotaro, Kashiwada, Tomomi, Ando, Koji, Shimokawa, Mototsugu, Saeki, Hiroshi, Akagi, Yoshito, Baba, Hideo, Maehara, Yoshihiko, Mori, Masaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877360/
https://www.ncbi.nlm.nih.gov/pubmed/33249761
http://dx.doi.org/10.1002/cam4.3618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877360/
https://www.ncbi.nlm.nih.gov/pubmed/33249761
http://dx.doi.org/10.1002/cam4.3618

Ejemplares similares